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The principal neutralizing domain (PND) of equine infectious anemia virus (EIAV) is located in the V3 region of SU. Genetic variation in the
PND is considered to play an important role in immune escape and EIAV persistence; however, few studies have characterized genetic variation in
SU during the inapparent stage of disease. To better understand the mechanisms of virus persistence, we undertook a longitudinal study of SU
variation in a pony experimentally inoculated with the virulent EIAVWyo. Viral RNA isolated from the inoculum and from sequential sera samples
was amplified by RT-PCR, cloned, and individual clones were sequenced. Of the 147 SU clones obtained, we identified 71 distinct V3 variants
that partitioned into five major non-overlapping groups, designated PND-1 to PND-5, which segregated with specific stages of clinical disease.
Genotypes representative of each group were inserted into an infectious molecular clone, and chimeric viruses were tested for susceptibility to
neutralization by autologous sera from successive times post-infection. Overall, there was a trend for increasing resistance to neutralizing antibody
during disease progression. The PND genotype associated with recrudescence late in infection was resistant to both type-specific and broadly
neutralizing antibody, and displayed a reduced replication phenotype in vitro. These findings indicate that neutralizing antibody exerts selective
pressure throughout infection and suggest that viral strategies of immune evasion and persistence change in the face of an evolving and maturing
host immune response.
© 2007 Elsevier Inc. All rights reserved.Keywords: Equine infections anemia virus; Broadly neutralizing antibody; Antigenic variation; Lentivirus persistenceIntroduction
Equine infectious anemia virus (EIAV) is a macrophage
tropic lentivirus that causes a lifelong persistent infection in
horses (Oaks et al., 1998; Sellon et al., 1992, 1994). Horses
infected with EIAV generally experience a clinically variable
disease course demarcated as acute, chronic and inapparent
stages of infection. The acute stage is associated with the initial
burst of viremia and rapid onset of clinical disease characterized⁎ Corresponding author. Department of Veterinary Microbiology and
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doi:10.1016/j.virol.2007.01.037by fever and thrombocytopenia (Sellon et al., 1994). During the
chronic stage of disease, recurrent episodes of fever, thrombo-
cytopenia, lethargy, inappetance, and progressive anemia are
interspersed with periods of clinical quiescence and reduced
virus load (Sellon et al., 1994). Most horses progress to the
inapparent stage of disease, distinguished by the absence of
clinical disease; yet, virus replication continues in the face of
virus-specific cellular and humoral immune responses. Reduced
levels of viremia and vigorous immune responses are present
during the long-term inapparent stage of disease, indicating that
immune control of virus plays a critical role in limiting the
manifestation of clinical signs. Thus, EIAV provides a good
model to examine mechanisms of immune control and virus
persistence during long-term lentivirus infection.
To date, most studies characterizing immune control of EIAV
have focused largely on the recurrent episodes of disease. These
Fig. 1. Clinical and serological profile of pony 524. (A) Clinical profile
following infection of pony 524 with EIAVWyo2078, fever episodes (columns,
primary y axis) and platelet counts (gray line, secondary y axis). Fever was
defined as rectal temperature greater than or equal to 101 °F. (B) Development of
neutralizing antibody to heterologous EIAVWSU-5. Neutralizing antibody titers
in pony 524 serum samples obtained at 0, 11, 35, 67, 89, 118, 201, 289, 498,
754, and 800 dpi were determined using a focus reduction assay as described in
Materials and methods. Results are expressed as the inverse of the serum
dilution that neutralized at least 75% of virus infectivity.
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are required during acute disease,while both humoral and cellular
immune responses are required for the termination of plasma
viremia during chronic EIAV infection (McGuire et al., 2002).
During chronic infection, the resolution of recurrent episodes of
disease has been causally associated with development of type-
specific neutralizing antibody (Carpenter et al., 1987; Hussain
et al., 1987; Kono et al., 1973; Kono, 1988; O'Rourke et al.,
1989; Payne et al., 1984; Rwambo et al., 1990; Salinovich et al.,
1986). Over time, the antibody response changes from one that is
of low avidity and nonneutralizing to one that is of moderate
avidity and neutralizing. In addition, the nature of the epitopes
recognized by humoral responses changes from linear epitopes to
more conformationally complex epitopes (Hammond et al.,
1997). In many EIAV-infected horses, this immune maturation is
accompanied by the development of broadly neutralizing
antibodies (Belshan et al., 2001; Hammond et al., 1997, 2000),
often in association with onset of the long-term, inapparent stage
of disease (Belshan et al., 2001; Hammond et al., 1997, 2000).
Studies of EIAV genotypes present during acute and chronic
stages of infection have demonstrated well-defined hypervari-
able regions within the surface envelope glycoprotein of EIAV
(Leroux et al., 1997, 2001). The third variable region exists in a
putative loop structure bound by cysteine residues and contains
two epitopes recognized by murine monoclonal antibodies (Ball
et al., 1992). This region, which has been termed the principal
neutralizing domain (PND), undergoes a high rate of genetic
variability in vivo. In addition to point mutations, there is
considerable variation in the length of the PND, which in some
cases is clearly due to duplication or deletions of PND sequence
(Leroux et al., 1997, 2001; Pang et al., 1997; Zheng et al., 1997a).
There is a large body of data describing genetic and antigenic
variation during successive fever episodes of equine infectious
anemia; however, relatively little is known about genotypes and
neutralization phenotypes of variants that predominate during
the long-term inapparent stage of disease. To characterize genetic
and antigenic changes associated with persistence, we undertook
a longitudinal analysis of the evolution of virulent EIAVWyo
through the inapparent stage of disease. The inapparent stage of
disease coincidedwith the onset of broadly neutralizing antibody
and a marked increase in genetic variability in the PND,
primarily due to size variation in V3 and increased point
mutations in V2 and V4. Over time, predominant variants showed
increasing resistance to type-specific and broadly neutralizing
antibody. A late febrile cycle at 800 dpi was associated with
predominance of a V3 variant that was resistant to broadly
neutralizing antibody and had reduced replication in vitro. These
findings suggest that neutralizing antibody exerts continuous
selective pressure and plays an important role in maintenance of
the inapparent stage of infection.
Results
Clinical profile of EIAVWyo-infected pony 524
The experimental inoculation and clinical disease course in
pony 524 were previously described (Belshan et al., 2001). Afterinoculation, pony 524 experienced a clinical disease course
characterized by recurring fever cycles interspersed with afebrile
periods ranging from days to months (Fig. 1). The initial acute
episode included a biphasic febrile response and thrombocyto-
penia, followed by a chronic period of seven recurrent fever
episodes which ranged from 2 to 6 days in length, and ended on
day 135. Thereafter, pony 524 remained afebrile except for two
fever episodes that occurred late in the study period at days 565
and 799. These two episodes were accompanied with thrombo-
cytopenia and increased viremia, consistent with disease
caused by EIAV. Virus-neutralizing antibodies to heterologous
EIAVWSU-5 appeared after the chronic fever cycles subsided
(201 dpi) and were maintained throughout the remainder of the
experiment. Therefore, the onset of inapparent infection was
associated with the appearance of broadly neutralizing antibody.
Pony 524 was euthanized during the long-term inapparent stage
of disease on day 878 as part of another study.
Envelope evolution during disease progression
The disease course in pony 524 provided an opportunity to
characterize the evolution of env genotypes through well-defined
158 B.A. Sponseller et al. / Virology 363 (2007) 156–165stages of disease, namely the acute, chronic, and inapparent stages
(Fig. 2). Of particular interest was the identification of variants that
persisted in the presence of broadly virus-neutralizing antibody.Acute stage of disease
The inoculum was characterized by a heterogeneous
population of amino acid (a.a.) variants. Of the 28 V2–V4
Fig. 2. Genetic variation in SU during successive stages of EIAV infection. The alignment of SU amino acid sequences obtained from sera of pony 524 is grouped
by dpi. All nucleotide sequences obtained from the inoculum and at sequential days post inoculation (DPI) were translated in the SU open reading frame. Amino acid
variants were named in the order they were identified, with identical variants given the same identifier, e.g. A.1. The sequence identifier is indicated at the left of the
sequence, with numbers in parentheses denoting the number of clones represented by that sequence. Dots (.) indicate an identical amino acid to the reference sequence,
A.1, at that position. Hyphens (-) indicate gaps in the sequence. Asterisks (*) indicate a premature stop codon in the SU ORF. The variable regions are denoted by
shaded boxes overlying the A.1 reference sequence: variable region 2, V2; variable region 3, V3; variable region 4, V4. Predicted N-linked glycosylation sites in A.1
are bolded. Numbering at the top of the alignment is based on start site of the SPeiav19 SU ORF. GenBank Accession numbers are EF405726-EF405796.
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predominant genotype, designated A.1, represented 32% of the
clones and is referred to as the founder sequence. The env
populations present during the acute period (12, 35 dpi) were
very similar to that found in the inoculum. Of the 26 clones
sequenced, we observed nine different a.a. variants, four of
which had been previously detected in the inoculum. Further,
the novel variants differed by only one amino acid substitution
relative to the founder sequence.
Chronic stage of disease
The chronic stage of disease (67, 89, 118 dpi) was char-
acterized by recurrent febrile cycles and the emergence of novel
genotypes, which resulted primarily from point mutations in the
previously defined variable regions. The most notable changes
were those that altered size, charge, or putative N-linked
glycosylation sites (PNGS) within V3. Variants that differed in
size relative to the founder sequence were a consequence of
insertions and/or deletions (indels) within V3, and appeared at 89
and 118 dpi (A.27, A.28, and A.34). Point mutations not only
altered the amino acid identity, but in some instances also altered
charge and/or the number and placement of PNGS. For example,
the substitutions of Y203 and/or P204 with H, which occurred in
several variants at 67 and 118 dpi, conferred a net increase in
positive charge. At day 67, D184N substitutions were frequently
paired with a N186T substitution, consistent with gain of a PNGS
(NXS/T). Other changes included premature stop codons between
V3 and V4 in three of the variants at 67 dpi and a predominant
L242V substitution at 118 dpi. Interestingly, the V3motif in A.17,
which differed from the founder sequence by deletion/insertion in
the PND, was previously detected in two independently derivedtissue culture-adapted biological clones (Malmquist et al., 1973;
O'Rourke et al., 1988).
Long-term inapparent stage of disease
The inapparent stage of disease (201, 289, 385, 437 dpi) was
characterized by a marked increase in genetic variation,
primarily due to indels within V3. Previous studies identified
insertions within the V3 region of the EIAVenvelope that arose
from duplication events during reverse transcription (Leroux et
al., 1997, 2001; Pang et al., 1997; Zheng et al., 1997a, 1997b).
However, the indels detected here appeared not to arise by
duplication, but rather from deletion of an existing motif and
insertion of a completely novel motif, which showed no
homology with EIAV sequences. This raised the possibility
that the insertions were of host origin. In support of this, a blast
search revealed that the predominant V3 insertion at day 437,
represented by A.55, had 97% identity with human MRNK1
RING zinc finger gene (GenBank accession AF192784). The
MRNK1-like insertion in EIAV A.55 was in the opposite
orientation of the RING zinc finger protein, and is therefore
unlikely to play a functional role during virus replication.
However, the fact thatMRNK-1 gene is highly conserved across
species (Gray et al., 2000, 2001) supports the hypothesis that the
V3 insertion present in A.55 arose as a consequence of
recombination with equine sequences.
It was possible that the EIAV/MRNK1 recombinant arose
during the course of infection of pony 524. However, the
EIAVWyo2078 inoculum has been maintained by serial in vivo
passage, and the recombination event could have occurred
during an earlier infection. To examine this, viral RNA from the
inoculum was amplified by semi-nested RT-PCR. The first
Table 1
SUA variants grouped according to V3 motif
Stage b DPI c Group a Total
1 2 3 4 5 6 7 Outliers d
Inoculum 27 e 0 0 0 0 0 0 2 29
Acute 12 12 0 0 0 0 0 0 0 12
35 13 0 0 0 0 0 0 0 13
Chronic 67 3 5 0 0 0 0 0 4 12
89 0 2 0 0 0 6 0 3 11
118 0 10 1 0 0 0 0 0 11
Inapparent 201 0 0 11 0 0 0 0 0 11
289 0 0 0 0 1 0 5 5 11
385 1 4 0 3 0 0 0 5 13
437 0 0 0 10 0 0 0 2 12
Late febrile 800 0 0 0 0 12 0 0 0 12
Total 56 21 12 13 13 6 5 21 147
a Variants were grouped according to amino acid similarity within the PND
region. Estimates of diversity, Pi and Theta, were measured within each group
and for outliers. Pi is the expected proportion of pairwise differences per
nucleotide site (nucleotide diversity). Theta measures the genetic variation as the
expected proportion of segregating sites, a calculation that incorporates the
mutation rate at each site. Low values estimating diversity support the groupings
by V3 motif (data not shown).
b Stage of disease.
c Days post inoculation at which variants were isolated.
d Variants so dissimilar that they did not segregate into one of the defined
groups.
e Number of variants in a group.
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insertion, while a primer within the MRNK1 insertion was used
for the nested amplification. Amplicons were cloned and
sequenced, and results indicated that the MRNK1 motif was
present in the inoculum (data not shown). Therefore, viral
populations dominant during inapparent infection included
genotypes pre-existing in the inoculum as well as genotypes
that evolved de novo during the course of infection.
Late febrile episode
The env population detected during the late febrile episode
(800 dpi) appeared more homogeneous than that observed
during the inapparent carrier stage. However, the predominant
V3 motif was very different than those previously observed, and
appeared to arise from deletion of one motif and insertion of
another. Interestingly, the predominant variant detected at day
800, SU-A.50, was present as a minor variant at day 289. The
emergence of pre-existing genotypes at different stages of
disease suggests continual, ongoing changes in the host immune
environment.
In summary, during the acute and chronic stages of infection,
recurrent febrile episodes were characterized by point mutations
in V3 and an overall low level of variation in the absence of
neutralizing antibody to heterologous virus. The inapparent
stage coincided with the onset of broadly neutralizing antibody
and a marked increase in genetic variability in the PND, which
was characterized by size variation in V3 and increased point
mutations in V2 and V4. These results are consistent with
diversifying selection associated with changes in immune
pressure during the progression of disease in EIAV-infected
horses.
Continual divergence of dominant genotypes throughout
infection
To better understand factors important in V3 evolution in
vivo, the entire V3 data set was aligned and grouped according to
amino acid similarity. Groupings were determined by inspection
of amino acid identity in two distinct contexts: low sequence
heterogeneity (the inoculum through 201 dpi) and high sequence
heterogeneity (289–800 dpi) (see Fig. 2). A total of 126 of 147
clones could be placed into seven groups (Table 1), with twenty-
one outliers that could not be grouped. Five of the groups,
designated PND-1 through PND-5, contained 12 or more
variants and represented 78% of the total population. Two
minor groups each contained six or fewer variants. To evaluate
the validity of V3 groupings based on inspection, the genetic
diversity within each group was estimated in terms of per-
nucleotide expected heterozygosity, or nucleotide diversity
within the V3 subregion of SU. Two estimates of nucleotide
diversity, π and θ, were calculated using DnaSP version 3.51. Pi
is the expected proportion of pairwise differences per nucleotide
site and is often referred to as nucleotide diversity. Theta
measures the genetic variation as the expected proportion of
segregating sites, a calculation that incorporates the mutation
rate at each site. Both estimates of diversity were below 4% for
each of the seven groups, but were nearly 20% for the outliers,indicating a high degree of similarity within each of the
designated groups. To quantitatively characterize the genetic
change between groups, estimates of divergence (between-
group diversity) were calculated. Between-group divergence
was measured as the average number of nucleotide substitutions
per site between groups, Dxy (Table 2). The increasing values of
divergence over time indicated ongoing genetic change in V3
away from the inoculum. Furthermore, the predominance of
particular V3 groups changed successively during progression
of disease (Table 1). PND-1 was predominant in the inoculum
and during the acute stage of disease; PND-2 was predominant
during the chronic stage of disease; PND-3 was predominant
early during the inapparent stage of disease; PND-4 was
predominant later during the inapparent stage of disease; and
PND-5 was predominant during the late febrile stage of disease.
This continual replacement of one predominant group by
another suggested ongoing changes in the fitness landscape
during the course of infection. Therefore, it was of interest to
evaluate the neutralization phenotypes represented by these
distinct, dominant genotypes.
Type-specific neutralizing antibody exerts selective pressure
during acute and chronic stages of EIAV
Antigenic variation is an important strategy of immune
evasion and lentivirus persistence. To examine whether the
observed genetic differences altered susceptibility to neutraliza-
tion by autologous pony 524 serum, chimeric viruses containing
V3 genotypes representative of each major group (Fig. 3) were
Table 2
Divergence between PND groups
Group a 1 2 3 4 5
1 0.000 0.038 b±0.002 0.028±0.005 0.299±0.015 0.471±0.024
2 0.000 0.044±0.006 0.331±0.027 0.478±0.040
3 0.000 0.255±0.028 0.315±0.034
4 0.000 0.697±0.173
5 0.000
a PND groupings are as described in Table 1.
b Between-group divergence was calculated as the average number of
nucleotide substitutions per site between groups, Dxy, ±standard error.
Table 3
Virus neutralizing antibody titers to chimeric virus containing representative
PND genotypes
Sera Virus
EIAVPND-1 EIAVPND-2 EIAVPND-3 EIAVPND-4 EIAVPND-5 EIAV19
d35 a <4 b <4 <4 <4 <4 <4
d67 16 <4 <4 <4 <4 <4
d89 128 <4 <4 <4 <4 <4
d118 128 <4 <4 <4 <4 <4
d201 128 4 4 <4 <4 4
d289 256 64 64 16 8 64
d385 256 64 64 32 4 64
d498 128 32 32 32 4 64
d567 nd c nd nd 64 4 64
d677 nd nd nd 32 4 64
d800 nd nd nd 128 32 nd
d878 128 32 32 128 16 64
TOBYd 128 nd 64 32 4 64
a Autologous sera from Pony 524 isolated at indicated days post-infection.
b Inverse of the serum dilution that gave a 75% reduction in EIAV focus-
forming units as compared to normal horse sera.
c Not done.
d Wild-type EIAVMA-convalescent serum.
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collected throughout infection. Low titered neutralizing anti-
body to the backbone virus, EIAV19, was first detected at
201 dpi, increased to a titer of 64 at 289 dpi, and remained at
that level through all subsequent time points (Table 3). The
neutralizing response to EIAV19 was similar to that observed for
EIAVWSU-5 (Fig. 1) and thus likely represents the broadly
neutralizing antibody associated with onset of the inapparent
carrier stage of disease (Belshan et al., 2001; Hammond et al.,
1997, 2000).
Neutralization assays using a single molecular clone do not
evaluate the entire virus population present at any given time
point. However, the EIAV-PND chimeric clones allowed us to
test the effect of specific changes in the predominant PNDs on
virus neutralization phenotype. Antibody capable of neutraliz-
ing EIAVPND-1 was first detected at 67 dpi, and rapidly
increased to a titer of 128 by 89 dpi. Subsequent serum samples
from pony 524 were able to neutralize EIAVPND-1 at the same or
higher titer. Therefore, the neutralizing antibody response to
EIAVPND-1 clearly differed from the response to EIAV19 in both
the time of onset and rate of development indicating that
EIAVPND-1 is antigenically distinct from EIAV19. Together,
these characteristics are consistent with a type-specific
neutralizing antibody response to EIAVPND-1. Importantly, the
appearance of high titered type-specific neutralizing antibody to
EIAVPND-1 was temporally correlated with the decline of the
PND-1 genotype (Table 1, Table 3), suggesting that neutralizing
antibody contributes to resolution of the acute stage of EIAV
infection.
EIAVPND-2 and EIAVPND-3 differed fromEIAVPND-1 by fewer
than 6 amino acids (Fig. 3), yet were clearly resistant to the type-
specific neutralizing antibody that was effective in controlling
EIAVPND-1. This is direct evidence that minor genetic changes in
PND can result in antigenic variation and immune selectionFig. 3. Amino acid sequence of the five major EIAV PND genotypes identified dur
generate chimeric infectious clones. Dots represent identity to the PND-1 protein s
representative PND chimeric proviral clones are indicated in parentheses. The amin
contiguous linear epitopes, ENT and DNT, identified by Ball et al. (1992), are indicaduring chronic stages of EIAV. Antibodies neutralizing EIAVPND-2
were not detected until 201 dpi, and achieved a maximum titer of
64 at 289 dpi. In contrast to the type-specific neutralization
response to EIAVPND-1, no temporal increase in neutralizing
antibody titer was associated with the appearance and decline of
the PND-2 sequence motif. In fact, the PND-2motif was found as
late as 385 dpi, well beyond the date that antibodies neutralizing
EIAVPND-2 were initially detected (Table 1). The neutralization
response to EIAVPND-2 was essentially the same as that to EIAV19,
with 2-fold differences in titer within the experimental error of the
assay. Therefore, EIAVPND-2 and EIAV19 appeared to be
neutralized by the antibody of similar specificity. While we
could not rule out the presence of a type-specific response to the
PND-2 genotype, we would have expected such antibody to be
found in earlier serum samples, to neutralize to higher titer, and to
be temporally associated with decline of the PND-2 genotype.
Together, this suggested the absence of high titered, type-specific
neutralizing antibody to the PND-2 genotype.
The neutralization profile to EIAVPND-3 followed a pattern
similar to that of EIAV19 and EIAVPND-2, consistent with the
activity of broadly neutralizing antibodies. These patterns
suggested that EIAVPND-2 and EIAVPND-3 were resistant to a
type-specific neutralization response, but were susceptible toing infection of pony 524. Sequences of representative PND genotypes used to
equence (top); hyphens represent gaps. The individual clones used to generate
o acid sequence of the infectious molecular clone EIAV19 is shown. The two
ted by single (ENT) or double (DNT) underline.
Fig. 4. Replication phenotype of chimeric viruses in vitro. Stocks of chimeric
virus were normalized to equivalent RT counts and inoculated in triplicate onto
(A) equine dermal cells or (B) equine monocyte-derived macrophages.
Supernatants were collected and assayed for virion RT activity over 14 days.
Results are expressed as mean RT counts/ml inoculum.
162 B.A. Sponseller et al. / Virology 363 (2007) 156–165broadly neutralizing antibody. These data are consistent with the
transition of type-specific antibody responses towards a more
broadly reactive immune response during the course of
infection (Hammond et al., 1997, 2000; Rwambo et al., 1990).
SU genotypes that persist during inapparent and late chronic
stages of infection show increasing resistance to neutralizing
antibody
The development of broadly neutralizing antibody coincided
with the onset of the inapparent stage of EIAV; however, it was
clear that there was ongoing virus replication throughout
infection. Therefore, it was of interest to examine the
neutralization phenotype of V2–V4 variants that were pre-
dominant during the inapparent stage of infection. Antibodies
neutralizing EIAVPND-4 were first detected at 289 dpi, prior to
the appearance and predominance of the PND-4 genotype at
385 and 437 dpi (Table 1 and Table 3). Thus, EIAVPND-4 had
increased resistance to neutralizing antibody as compared to
chimeric viruses containing genotypes predominant earlier in
infection. EIAVPND-5 was poorly neutralized by sera collected
at 289, 385, 498, 567, and 677 dpi. We did observe an increase
in neutralizing antibody activity to both EIAVPND-4 and
EIAVPND-5 at 800 dpi, which may reflect the presence of
a type-specific neutralizing antibody response. However,
EIAVPND-5 was clearly more resistant to neutralization by
broadly neutralizing antibody that was effective in neutralizing
earlier genotypes. The sequential appearance of PND genotypes
with increasing resistance to neutralizing antibodies is indica-
tive of continual, ongoing antibody selection through all stages
of EIAV infection.
Howe et al. (2002) identified changes in V3 and V4 of EIAV
SU that were associated with resistance to neutralization by sera
from other EIAV-infected horses (Howe et al., 2002). We tested
the susceptibility of our panel of chimeric viruses to neutraliza-
tion by heterologous wild-type sera containing high titered,
broadly neutralizing antibody (Table 3). Chimeric viruses con-
taining PND-1, -3, and -4 genotypes were neutralized to varying
degrees by heterologous serum. Importantly, EIAVPND-5 was
clearly resistant to neutralization by heterologous, wild-type
serum. The PND-5 genotype was predominant during recrudes-
cence of disease at 800 dpi, suggesting that genetic changes
conferring resistance to broadly neutralizing antibodymay allow
immune escape and recrudescence of clinical disease following a
lengthy clinically quiescent period. As such, neutralizing
antibody likely plays a critical role in controlling levels of
virus replication and maintaining clinical quiescence during
long-term persistent infection.
Neutralization resistance is associated with altered replication
phenotype in vitro
Studies with primate lentiviruses have reported that
resistance to broadly neutralizing antibody can be associated
with reduced replication fitness in vitro (Joos et al., 2005;
Nakowitsch et al., 2005). The five chimeric viruses were tested
for replication efficiency in equine dermis (ED) cells andprimary monocyte-derived macrophage (MDM) cultures. Virus
stocks were normalized for reverse transcriptase (RT) activity
and inoculated in triplicate onto both ED cells and MDM.
Supernatant was collected at varying time post inoculation and
assayed for virion reverse transcriptase (RT) activity. All
viruses, including the parental EIAV19 virus, replicated to
higher titer in ED cells compared to MDM (Fig. 4). Therefore,
the wild-type V2–V4 motifs did not alter cell tropism in the
EIAV19 background. In both cell types, however, EIAVPND-5
replicated more slowly and achieved a lower titer than EIAV19
and the other four chimeric viruses. It is possible that
incompatibility between the PND-5 V2–V4 sequences and
the cell-adapted EIAV19 backbone restricts the rate and level of
virus replication in vitro. Alternately, sequences within PND-5
may confer a reduced replication phenotype in vitro and,
perhaps, in vivo. Genotypes conferring resistance to broadly
neutralizing antibody and reduced replication capacity in vivo
may have a selective advantage over the course of a long-term
persistent infection in an immunocompetent host.
Discussion
Envelope variation during clinical stages of equine infec-
tious anemia virus infection has been well documented;
however, there is little known about genotypic variation and
163B.A. Sponseller et al. / Virology 363 (2007) 156–165neutralization phenotypes of variants that predominate during
the long-term inapparent stage of disease. To gain insight into
envelope genotypes associated with persistence during long-
term infection, we studied genetic and antigenic evolution of
EIAV env throughout the acute, chronic, and inapparent stages
of disease. The inapparent stage of disease coincided with the
onset of broadly neutralizing antibody and a significant
increase in genetic variability in the PND. Genetic variation
within the region encompassing V2 through V4 was character-
ized by size variation in V3 and increased point mutations in
V2 and V4. As infection progressed, predominant variants
showed increasing resistance to type-specific and broadly
neutralizing antibody. A late fever episode at 800 dpi was
associated with the predominance of a V3 variant resistant to
broadly neutralizing antibody and displaying a reduced
replication phenotype in vitro. These data indicate that neu-
tralizing antibody exerts continuous selective pressure through-
out infection, and plays a key role in maintenance of the
inapparent stage of disease.
It has been more than 30 years since Kono and colleagues
first proposed antigenic variation and escape from neutralizing
antibody as mechanisms of EIAV persistence (Kono et al.,
1973). Since then, numerous studies have identified genetic
variation in env at successive febrile cycles, often in association
with changes in antigenic phenotype (Leroux et al., 1997, 2001;
Pang et al., 1997; Zheng et al., 1997a, 1997b). However, few
studies have directly explored the relationship between genetic
changes in the EIAV SU and their effect on neutralizing
phenotype. In this study, we used chimeric molecular clones in
conjunction with autologous sera to directly correlate genetic
changes in the V2–V4 genotype with antigenic variation and
escape from neutralizing antibody during the acute, chronic, and
inapparent stages of EIAV infection. Type-specific neutralizing
antibody developed early in infection and neutralized chimeric
virus containing the predominant V2–V4 genotype detected in
the inoculum and throughout the acute stage of infection.
Consistent with Kono's model, there was rapid selection for
antigenic variants, as the antigenically distinct PND-2 genotype
quickly replaced PND-1. Curiously, the PND-2 genotype
persisted throughout the chronic stage of infection and we
observed only limited genetic changes at successive febrile
cycles. Additionally, we did not observe successive waves of
type-specific neutralizing antibody temporally associated with
successive febrile cycles. Rather, the maturation and broadening
of the neutralizing antibody response over time selected for env
genotypes with increasing resistance to broadly neutralizing
antibody. Similarly, Howe et al. (2002) showed that env
genotypes dominant in late febrile cycles are more resistant to
neutralization than genotypes dominant early after infection
(Howe et al., 2002). These results suggest that evolution of
increased resistance to broadly neutralizing antibody follows
maturation of humoral immunity. This, combined with the
reduced replication phenotype conferred by the PND-5
genotype, suggests that viral strategies of immune evasion
change in response to an evolving and maturing host immune
response. Overall, these findings clearly support a model of
neutralizing antibody selection of antigenic variants and furtheremphasize the importance of humoral immunity in control of
virus replication in vivo. Over the course of infection,
neutralizing antibody exerted continuing selective pressure on
an evolving population of viral genotypes. Early after infection,
relatively few genetic changes were required for immune
escape; however, the onset of broadly neutralizing antibody
resulted in an increasingly diverse population characterized by
large insertions in V3. Previous studies have reported insertions
and deletions within V3 during the course of EIAV infection
(Leroux et al., 1997, 2001; Spyrou et al., 2005; Zheng et al.,
1997a, 1997b, 2000). In most cases insertions were composed
of duplicated EIAV sequence, suggestive of recombination
during reverse transcription (Zheng et al., 1997a, 1997b). Here,
the marked size variation in V3 was not due to simple deletions,
or to insertions of repeated sequence. We observed en bloc
deletions with concomitant insertion of large, novel sequences
that altered the number and position of PNGS. Interestingly, the
V3 motifs were noticeably larger throughout the inapparent
stage of disease as compared to the acute and chronic stages of
disease, suggesting that size variation may confer a selective
advantage in the face of broadly neutralizing antibody. Two
epitopes for murine neutralizing antibody are found within V3
(Ball et al., 1992). The V3 insertions may confer resistance to
neutralizing antibody by radically changing amino acids within
neutralizing epitopes. It is also possible that size variation and/
or the addition of PNGS within V3 masks neutralizing epitopes
through SU conformational changes in a manner similar to that
proposed for HIV-1 neutralization escape variants (Dacheux et
al., 2004; Wei et al., 2003). Identification of broadly neutraliz-
ing epitopes and delineating how changes in PND-5 confer
neutralization resistance will aid in the design of effective
lentivirus vaccines.
Materials and methods
Experimental infection and isolation of viral genotypes
The experimental infection of pony 524 was previously
reported (Belshan et al., 2001). The pony was infected with 103
horse infectious doses of virulent Wyoming strain of EIAV
(EIAVWyo). Sera and plasma were collected during clinical and
subclinical infection and stored at −80 °C until analyzed.
Viral RNAwas isolated from sera and the V2–V4 region of
the env gene was amplified using methods previously described
(Belshan et al., 2001). Primers were chosen from conserved
regions of SU as determined from EIAV env sequences
available in GenBank data. The upstream primer was 5′-
AATGCTGGGGTTCCTTCC-3′ and the downstream primer
was 5′-ACACAGCCTGATTGGATG-3′. Two microliters of
PCR product were ligated into pGEM-T vectors according to the
manufacturer's recommendations and transformed into Escher-
ichia coli DH-5α. Individual clones were sequenced bidir-
ectionally with primers to vector sequences flanking the insert.
All sequencing was performed by the Iowa State University
DNA Synthesis and Sequencing Facility using an automated
DNA sequencer. All nucleotide sequences were translated in the
SU open reading frame. Amino acid variants were named in the
164 B.A. Sponseller et al. / Virology 363 (2007) 156–165order they were identified, with identical variants given the same
name, e.g., A.1.
Amino acid alignment and analysis of diversity and divergence
A total of 147 clones was obtained from the wild-type in-
oculum and sequential serum samples. Clones were sequenced,
translated in the SU open reading frame, aligned, and analyzed
using BioEdit 4.8.6 (Hall, 1999). Sequences were aligned with
ClustalW and manually optimized to adjust for insertions and
deletions. The genetic diversity of each group was estimated in
terms of per-nucleotide expected heterozygosity, or nucleotide
diversity within the V3 subregion of V2–V4. Two estimates of
nucleotide diversity, θ and π, were calculated using DnaSP
version 3.51. Between group divergence was measured as the
average number of nucleotide substitutions per site between
groups, Dxy.
Cell lines
Equine dermis cells (ED, ATCC CCL 57) and canine
fibroblast cells (Cf2Th, ATCC CRL 1430) were maintained in
Dulbecco's modified Eagles medium (DMEM) supplemented
with antibiotics and fetal calf serum. Monocyte-derived
macrophage cultures (MDM) were established as previously
described (Raabe et al., 1998; Smith et al., 1998). Briefly, whole
blood was obtained from EIAV-free horses by jugular veni-
puncture. Mononuclear leukocytes were banded by centrifuga-
tion at 750×g on a discontinuous histopaque gradient,
resuspended in DMEM containing 10% newborn calf serum
(NCS) and 20% normal horse serum (NHS), and seeded at
2×107 cells/cm2 in 24-well tissue culture plates. Monocytes
were allowed to adhere overnight at 37 °C and nonadherent cells
were removed from the cultures by washing twice with Hank's
buffered saline solution (HBSS) containing 2%NCS. Cells were
maintained in DMEM containing 10% NCS, 20% NHS, and
antibiotics.
Generation of chimeric viruses containing representative
wild-type genotypes
Plasmids containing representative env genotypes were
digested with SphI/Bsu36I, and the SU fragment (a.a. 142–257,
Fig. 2) containing the variant sequence was directionally cloned
into the molecular clone pSPeiav19 (Payne et al., 1994) to
generate a full-length infectious chimeric proviral clone. Plasmids
containing chimeric env were verified by nucleotide sequencing
and then co-transfected into Cf2Th cells with pSV5Neo using
liposome-mediated transfection (TransIT®-LT, Mirus, Madison,
WI). Transfectants were selected in G418, and resistant cell
clones were expanded in 24-well tissue culture plates and assayed
for virus production using a reverse transcriptase (RT) assay
(Carpenter and Chesebro, 1989). RT-positive clones were
expanded for production of virus stocks, which were aliquoted
and stored at −70 °C. Virus stocks were resequenced and titered
using a focal immunoassay which employs a chromogenic
method of detection (Carpenter et al., 1990).Virus neutralization assays
Virus neutralization was determined using a focal reduction
assay on ED cells (Carpenter et al., 1990). Sera were heat
inactivated to destroy complement, serially diluted two-fold in
supplemented DMEM, and incubated at 37 °C for 1 h with 550
focus forming units (FFU) of virus. Quadruplicate wells of ED
cells in 12-well plates were inoculated with the virus–serum
mixture in the presence of 4 μg polybrene, and the culture media
were changed the following day. Cells were incubated for an
additional 72 h, fixed with ice-cold methanol, and foci of EIAV-
infected cells were detected by immunocytochemistry and
enumerated. Results were expressed as the serum neutralization
titer, defined as the highest serum dilution that gave a 75%
reduction in FFU as compared with pre-inoculation and negative
control serum.
Characterization of virus replication
Stocks of chimeric virus were assayed for RT activity
(Carpenter and Chesebro, 1989) and equivalent RT counts were
inoculated in triplicate onto ED and MDM. The cells were
washed and media replaced the day after inoculation. Super-
natant was collected following the media change and every 2
days for a 2-week period. Supernatants were assayed for virus
RT-activity, expressed as cpm/μl supernatant.
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